DISP-01. IMMUNOTHERAPY ADMINISTRATION RATES IN PATIENTS WITH BRAIN METASTASES: IMPACT OF END STAGE RENAL DISEASE AND DIALYSIS

Abstract INTRODUCTION Comorbid conditions such as end-stage renal disease (ESRD) are common in patients with a diagnosis of brain metastasis (BM). Renal replacement therapy for ESRD typically includes hemodialysis or peritoneal dialysis. However, the efficacy immunotherapy (IT) delivery dialyzed is not well understood. Therefore, treatment modalities BM and must be considered during clinical decision-making. This study aimed to determine rate IT administration on dialysis using network real-world data. METHODS Data were collected from TriNetX (TriNetX, Inc., Cambridge, MA), research that provides data access 92 healthcare organizations globally. The independent variables included ‘secondary malignant neoplasm brain’, ‘introduction antineoplastic, monoclonal antibody’, ‘pembrolizumab’, ‘nivolumab’, ‘ipilimumab’, ‘ESRD’, ‘dependence dialysis’ ‘dialysis services procedures’. Dialyzed identified having received within 3 months before 5 years after their metastases diagnoses. Rates measured concomitant use, lack thereof. RESULTS Two patient cohorts neoplasms identified: cohort 3,593 non-dialyzed 525,831 patients. cohorts’ mean age at index was 64.7 years; 43% female. Of those, 81 (2.25%). 60.7 52% From this cohort, 19,347 (3.68%). Patients less likely receive than those (odds ratio: 0.604, 95% confidence interval: 0.484-0.753, P < 0.0001). CONCLUSION may selected against candidates IT. Given relative scarcity size potential implications dialysis, prospective studies will vital improving BM.